Biography
Dr Annabel Smith is a strong advocate for clinical trials and local research, ensuring her patients have access to the latest treatment options close to home. She brings a holistic, evidence-based approach to her practice and her patients benefit from her clinical research background and deep understanding of cancer care.
Dr Annabel Smith is a passionate medical oncologist at Icon Cancer Centre Adelaide. Born on the Mid North Coast, Dr Smith completed her Bachelor of Medicine, Bachelor of Surgery (MBBS) at James Cook University with a focus on rural, remote and indigenous health. She spent her early physician years in Brisbane, Queensland before relocating to Adelaide to complete her basic physician training at Flinders Medical Centre. Dr Smith subsequently undertook specialist medical oncology training at Flinders Medical Centre, The Queen Elizabeth Hospital (TQEH), Royal Adelaide Hospital and Royal Darwin Hospital.
Dr Smith maintains an active interest in clinical trials, medical education and research. Alongside her clinical work and tutoring, she regularly reviews publications for peer reviewed journals and organises formal training events for South Australian medical oncology registrars. Dr Smith also completed a local clinical trials and research fellowship at TQEH Clinical Trials Unit where she was directly involved in the care of numerous clinical trial patients. Outside of work, Dr Smith is a local surf life saver and outdoors enthusiast.
Publications
Insights From the IDEA Collaboration: Are They Enough? A. Smith, B. Geerinckx & T.J. Price. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2022; 40(16): 1843-1844.
Immunotherapy use in oesophagogastric cancers—a review of the literature. A. Smith, A. Roy, C.S. Karapetis, C.S. et al. British Journal of Cancer, 2022.
Duration of immunotherapy–should we continue ad infinitum? A. Smith, G. Shaghayegh, A.M. Menzies & R. Roberts‐ Internal Medicine Journal, 2020; 50(7):865-8.
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. D.L. Chan, E. Segelov, R.S. Wong, A. Smith, R.A. Herbertson, B.T. Li, N. Tebbutt, T. Price & N. Pavlakis. Cochrane Database of Systematic Reviews, 2017. (6)
A clinical audit of anal cancer in a single tertiary centre over 10 years. P.S. Kok, S. Pendlebury, A. Smith, S. Jarvis & E. Segelov E. Clinical Oncology Society of Australia Annual Scientific Meeting 2013: Cancer Care Coming of Age 2013.